DFTX
The table below shows Definium Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $117.67M | $65.30M | $52.12M | $36.17M | $34.79M | $18.63M |
| SG&A | $48.64M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $38.62M |
| $41.74M |
| $30.16M |
| $59.06M |
| $14.40M |
| Operating income | -$166.31M | -$103.92M | -$93.87M | -$66.33M | -$93.85M | -$33.03M |
| Income tax | $0.00 | - | - | - | -$1.16M | - |
| Net income | -$183.79M | -$108.68M | -$95.73M | -$56.80M | -$93.04M | -$33.94M |
| EPS (diluted) | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | - |